Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GlycoMimetics (GLYC – Research Report) and Gossamer Bio (GOSS – Research Report).
GlycoMimetics (GLYC)
GlycoMimetics received a Hold rating from H.C. Wainwright analyst Edward White today. The company’s shares closed last Monday at $0.40.
According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for GlycoMimetics with a $6.50 average price target.
See the top stocks recommended by analysts >>
Gossamer Bio (GOSS)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Gossamer Bio today and set a price target of $10.00. The company’s shares closed last Monday at $0.74.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gossamer Bio with a $6.75 average price target, an 800.2% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GLYC:
